Price
No data yet.
Social Signal Score
Analyst Ratings
12 analystsRevenue
$76.38M+11.38%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Nicholas Johnson
- Sector
- Consumer Cyclical
- Industry
- Personal Products & Services
- Employees
- 380
- Beta
- 0.73
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- 3.82
Financials
Revenue
$76.38M+11.4%Net Income
$-3.10M-151.1%EBITDA
$-2.99M-129.4%Free Cash Flow
$728.0K-87.1%EPS (diluted)
$-0.28-154.9%Shares Outstanding (diluted)
11.13M-6.8%Operating Expenses
$57.72MCash & Debt
$169.82MReturn of Capital
$83.0KRevenue by Segment (annual)
$301.56MDividend per Share
$1.65Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $385.79M | $-18.67M | $-1.70 |
| 2024 | $602.46M | $2.09M | $0.19 |
| 2023 | $1.07B | $99.42M | $9.10 |
| 2022 | $1.60B | $143.57M | $12.82 |
| 2021 | $1.53B | $164.03M | $14.01 |
| 2020 | $934.84M | $102.86M | $8.74 |
| 2019 | $713.67M | $77.92M | $6.62 |
| 2018 | $501.00M | $55.79M | $4.67 |
| 2017 | $301.56M | $27.72M | $2.32 |
| 2016 | $274.53M | $17.84M | $1.51 |
| 2015 | $272.77M | $20.06M | $1.68 |
| 2014 | $285.29M | $13.18M | $1.04 |
| 2013 | $356.89M | $23.97M | $1.74 |
| 2012 | $356.71M | $15.88M | $1.16 |
Valuation
MEDhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
50-37.50%Social Signal Score
Mentions (7)
- Newsglobenewswire.com·5d ago·Neutral
What Are the 5 Signs of Poor Metabolic Health Adults May Overlook? Baltimore, MD, Oct. 01, 2026 (GLOBE NEWSWIRE) -- The signs of poor metabolic health can be difficult to analyze without a clinical framework. Trilivy™, a science-backed, coach-guided metabolic health system, points to five frequently overlooked patterns adults can recognize before noticeable weight and energy fluctuations.
View source ↗ - Newsglobenewswire.com·7d ago·Negative
Why Weight Loss Plateaus Happen: 5 Metabolic Causes Trilivy™ is designed to address the challenges of metabolic dysfunction Clients on Trilivy's Reset 5 & 1 Plan who work with a coach lose up to 10 times more weight and 17 times more fat compared to self-directed approaches* Baltimore, MD, Sept. 29, 2026 (GLOBE NEWSWIRE) -- A weight loss plateau is one of the most common reasons people abandon a structured weight loss effort altogether.
View source ↗ - Newszacks.com·31d ago·Neutral
Medifast's 3.0 Strategy Takes Shape: Can It Restore Profitable Growth? MED is shifting toward metabolic health with its 3.0 strategy, targeting broader growth, greater efficiency and a return to profitability.
View source ↗ - Newszacks.com·33d ago·Neutral
Why Is Medifast (MED) Down 7.6% Since Last Earnings Report? Medifast (MED) reported earnings 30 days ago. What's next for the stock?
View source ↗ - Newszacks.com·40d ago·Neutral
Can Medifast Capitalize on Rising GLP-1 Use With Metabolic Health? MED's Trilivy launch marks a major metabolic-health shift, backed by a 10-year roadmap and growing GLP-1 market focus.
View source ↗ - Newszacks.com·40d ago·Positive
All You Need to Know About Medifast (MED) Rating Upgrade to Buy Medifast (MED) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
View source ↗ - Newszacks.com·54d ago·Positive
Can Medifast's Coach Productivity Gains Help Revive Revenue Growth? MED's improving coach productivity and client retention point to stabilization, but a shrinking coach base remains a challenge.
View source ↗
Earnings
Mon, Nov 9(in 5 weeks)
Consensus estimate $-0.35 per share
Typical surprise +56.9% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Aug 3$-0.28 vs $-0.65beat
- Mon, May 4$-0.19 vs $-0.55beat
- Tue, Feb 17$-0.55 vs $-0.76beat
- Mon, Nov 3$-0.21 vs $-0.01miss
- Mon, Aug 4$0.23 vs $-0.19beat
- Mon, Apr 28$-0.11 vs $-0.25beat
Estimates and results for MED via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by MED officers and directors.
- Bought
- $1.7m
- Sold
- $386k
13 trades
4 trades
- Chard Daniel Rsold
- Chard Daniel Rsold
- Kiai Parsabought
- Kiai Parsabought
- Kiai Parsabought
- Kiai Parsabought
- Kiai Parsabought
- Kiai Parsabought
83 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Donna Shalalahouse · FL27 · disclosed Apr 27, 2020 (308d later)Sell$1,001 - $15,000
- Donna Shalalahouse · FL27 · disclosed Apr 27, 2020 (363d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.